Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Glioblastoma Institute
Tumor Boards
Colleague Insights
Living Resources
Conferences
Video Expert Opinion
Sign in
Join now

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Brain Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

featured
Published in Brain Cancer

Expert Opinion / Cases · July 23, 2021

59 Year Old Male, KPS 90, Initially Diagnosed With a Right Temporal Glioblastoma

Martin Tom MD

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Martin Tom MD

Discuss This item Follow

No comments yet, be the first to start the discussion!

  • ruofan huang

    Jul 24, 2021

    clinical trials

  • Alex Y

    Jul 24, 2021

    Run liquid biopsy RGCC on fresh tumor or blood & treat accordingly to sensitivity. 
Rego can be be an option but dosage must be lowest as RPLS is possible same as with avastin. 
Summary GENE MARKERS ARE NEEDED to further elucidate correct chemotype for this patient

  • Dorothy-Myra Sackey

    Jul 24, 2021

    treat post operative necrosis

  • Tolga Tuncer

    Jul 30, 2021

    1) Why was the adjuvant TMZ only 3 mos? 2) Why did an unmethylated GBM NOT get Novo TTF-1 in adjuvant or concurrent setting 3) Candidate for AGILE study?

  • Al Musella

    Aug 08, 2021

    1. FTB map. If it shows likely tumor, stereotactic radiosurgery to the new lesion, or LITT.
2. Optune
3. Val-083. Possibly via the AGILE study but might be better to get it on compassionate use along with Optune.
4. Viral therapy. Maybe PVSRIPO + Pembrolizumab.

  • Nov 18, 2024

    Pending Moderator approval.
    Delete

Further Reading

Recently Updated